Below are the best information and knowledge on the subject new treatment for temporal arteritis compiled and compiled by our own team alltopus:
1. Current advances in the treatment of giant cell arteritis: the role of biologics
Date Submitted: 02/18/2021 04:34 PM
Average star voting: 3 ⭐ ( 18696 reviews)
Match with the search results: was approved by the Food and Drug Administration in 2017 to treat temporal arteritis. This medication is given as a subcutaneous injection. The patient should not smoke, and alcohol should be kept to a minimum….. read more
2. A new era for giant cell arteritis | Eye
Date Submitted: 05/13/2021 05:15 PM
Average star voting: 3 ⭐ ( 38253 reviews)
Summary: The landscape of the investigation and management of giant cell arteritis (GCA) is advancing. In this review we will outline the recent advances by searching the current English literature for relevant articles using key words of giant cell arteritis, temporal arteritis, Horton’s disease, investigation, and treatment. Delay in diagnosis, diagnostic uncertainty and glucocorticoid (GC) morbidity are among the highest concerns of clinicians and patients in this disease area. The positive news is that fast track pathways, imaging techniques and new therapies are emerging for routine management of GCA. Future directions for intervention in the treatment paradigm will be discussed.
Match with the search results: The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell ……. read more
3. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations – Arthritis Research & Therapy
Date Submitted: 08/25/2020 10:57 PM
Average star voting: 5 ⭐ ( 90600 reviews)
Summary: Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell arteritis (GCA). However, limited data exist on the effectiveness and safety of TCZ for GCA in real-world clinical practice. This was a retrospective, single-center analysis of patients with GCA treated with intravenous or subcutaneous TCZ (2010–2018). Outcomes evaluated before and after TCZ initiation included occurrence of flare, time to flare, annualized flare rate, flare characteristics (i.e., polymyalgia rheumatica [PMR] symptoms, cranial manifestations), prednisone use, and safety. Flare was defined as the recurrence of unequivocal GCA manifestations requiring treatment intensification. Subgroup analyses of patients with PMR or visual manifestations at GCA diagnosis were performed. Sixty patients with GCA were included. The median (IQR) disease duration before and after the start of TCZ was 0.6 (0.2–1.6) and 0.5 (0.3–1.4) years, respectively. At least 1 flare was observed in 43 patients (71.7%) before and in 18 (30.0%) after TCZ initiation. Median (IQR) time to flare was 0.5 (0.3–0.7) years before TCZ treatment and 2.1 (0.6–2.6) years after TCZ initiation (HR 0.22; 95% CI 0.10–0.50; p = 0.0003). The annualized flare rate significantly decreased following TCZ use (before TCZ 1.4 [95% CI 1.0–2.1]; after TCZ 0.6 [95% CI 0.3–1.0] events/year; p < 0.001). Similar improvements were observed in patients with visual manifestations or PMR symptoms at GCA diagnosis. TCZ reduced the incidence of new visual manifestations, and no flares associated with permanent vision loss occurred while patients were receiving TCZ. Mean (SD) prednisone dose at TCZ onset and at the end of follow-up was 30 (18.3) and 5 (6.9) mg/day, respectively (p < 0.0001). After TCZ initiation, 46.6% of patients successfully discontinued prednisone. The incidence of adverse events, primarily attributed to glucocorticoids, was similar before and after TCZ initiation. In this real-world setting, TCZ improved GCA clinical outcomes significantly and demonstrated effectiveness in the subgroups of patients with PMR symptoms and GCA-related visual manifestations at GCA diagnosis. No new cases of blindness occurred after TCZ initiation. Adverse events, many attributable to glucocorticoids, were comparable before and after TCZ treatment.
Match with the search results: Although glucocorticoids have been the mainstay of treatment for almost 7 decades, new therapeutic options have emerged. This review aims to ……. read more
4. MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial – Full Text View – ClinicalTrials.gov
Date Submitted: 07/01/2019 12:35 PM
Average star voting: 5 ⭐ ( 49782 reviews)
Match with the search results: The Food and Drug Administration recently approved tocilizumab (Actemra) to treat giant cell arteritis. It’s given as an injection under your ……. read more
5. Giant Cell Arteritis Part 2: Treatment – This Changed My Practice
Date Submitted: 06/11/2019 04:33 PM
Average star voting: 5 ⭐ ( 10123 reviews)
Summary: Giant cell arteritis (GCA) is the most common vasculitis in adults above 50 years of age. GCA is a rheumatological emergency. Rapid diagnosis and treatment are required to reduce the risk of complications.
Match with the search results: Methotrexate is the recommended first-line treatment and anchor drug in the management of rheumatoid arthritis. … It is also effective in a wide ……. read more
6. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
Date Submitted: 05/11/2020 12:21 PM
Average star voting: 5 ⭐ ( 18830 reviews)
Match with the search results: Methotrexate has been tested as a steroid-sparing agent and in refractory GCA [75,76,77]. Currently EULAR recommends considering methotrexate in ……. read more
7. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
Date Submitted: 07/12/2019 07:31 AM
Average star voting: 4 ⭐ ( 47831 reviews)
Summary: AbstractObjective. The efficacy of tocilizumab (TCZ) in GCA is supported by two randomized controlled studies, in which TCZ allowed remission to be achieved aft
Match with the search results: GLUCOCORTICOID-SPARING AGENTS — Adjunctive treatment for giant cell arteritis (GCA) may be used in situations where glucocorticoid-related ……. read more
8. Can Giant Cell Arteritis Be Cured?
Date Submitted: 12/12/2020 09:20 AM
Average star voting: 4 ⭐ ( 50531 reviews)
Summary: Giant cell arteritis (GCA) inflames the arteries. Along with symptoms like headaches, pain, and fatigue, it can cause blindness and other serious complications if you don’t treat it. Treatment with steroid medications is the main way to stop inflammation of GCA and prevent complications. Read on to learn more.
Match with the search results: Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for remission maintenance and glucocorticoid sparing in ……. read more